Deka Bank Deutsche Girozentrale Atara Biotherapeutics, Inc. Transaction History

Deka Bank Deutsche Girozentrale

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	BUY	$8.44 - $16.89 $23,632 - $47,292	2,800 Added 9.86%	31,200 $286,000
Q4 2021 Feb 02, 2022	BUY	$14.7 - $19.89 $11,760 - $15,912	800 Added 2.9%	28,400 $476,000
Q4 2020 Mar 12, 2021	BUY	$12.67 - $26.23 $261,002 - $540,338	20,600 Added 294.29%	27,600 $575,000
Q3 2020 Oct 29, 2020	BUY	$11.92 - $15.87 $83,440 - $111,090	7,000 New	7,000 $89,000
Q4 2019 Feb 04, 2020	SELL	$10.89 - $16.79 $78,408 - $120,888	-7,200 Closed	0 $0

Q3 2019 Nov 14, 2019	SELL	$12.03 - $19.94 $86,616 - $143,568	-7,200 Reduced 50.0%	7,200 $97,000
Q2 2019 Aug 01, 2019	BUY	$19.05 - $41.04 $106,680 - $229,824	5,600 Added 63.64%	14,400 $292,000
Q1 2019 May 10, 2019	BUY	$28.4 - $41.74 $45,440 - $66,784	1,600 Added 22.22%	8,800 $356,000
Q4 2018 Feb 12, 2019	SELL	$30.9 - $42.97 $49,440 - $68,752	-1,600 Reduced 18.18%	7,200 $248,000
Q3 2018 Nov 09, 2018	SELL	$35.05 - $43.5 $7,009 - $8,700	-200 Reduced 2.22%	8,800 $0
Q1 2018 May 03, 2018	SELL	$18.0 - $48.35 $3,600 - $9,670	-200 Reduced 2.17%	9,000 $342,000
Q3 2017 Nov 06, 2017	BUY	$13.25 - $17.05 $121,900 - $156,860	9,200	9,200 $132,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $781M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.